Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.45 |
| ▸ | JAK3 | P52333 | 3/20 | 0.45 |
| ▸ | MAPK3 | P27361 | 4/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.40 |
| ▸ | ULK3 | Q6PHR2 | 2/20 | 0.40 |
| ▸ | STK17B | O94768 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 8/20 | 0.40 |
| ▸ | ITK | Q08881 | 5/20 | 0.40 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.39 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27240933 | 0.93 | LRRK2 (0.43) | BTKJAK3MAPK3LRRK2EGFR | |
| SCHEMBL30931281 | 0.92 | JAK3 (0.43) | BTKJAK3LRRK2EGFRITK | |
| SCHEMBL27240858 | 0.92 | JAK3 (0.43) | BTKJAK3LRRK2EGFRITK | |
| SCHEMBL27240955 | 0.91 | JAK3 (0.44) | BTKJAK3MAPK3EGFRITK | |
| SCHEMBL30931287 | 0.90 | BTK (0.43) | BTKJAK3EGFRITK | |
| SCHEMBL27240768 | 0.90 | BTK (0.43) | BTKJAK3EGFRITK | |
| SCHEMBL27240829 | 0.89 | JAK3 (0.41) | BTKJAK3EGFRITK | |
| SCHEMBL27240838 | 0.89 | JAK3 (0.41) | BTKJAK3EGFRITK | |
| SCHEMBL27240973 | 0.89 | JAK3 (0.41) | BTKJAK3EGFRITK | |
| SCHEMBL30931264 | 0.88 | EGFR (0.45) | BTKJAK3EGFRITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | TYRA BIOSCIENCES, INC. | 2024-06-13 | — | — | US | claimed |
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | TYRA BIOSCIENCES, INC. | 2024-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | DPYD, TYMP, TYMS | BTK 2153/4885JAK3 1800/4885MAPK3 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.